Candidate pharmacogenetic signals at CCL2 and ITPA associated with JAK inhibitor response in Taiwanese rheumatoid arthritis - PubMed
7 hours ago
- #rheumatoid arthritis
- #JAK inhibitors
- #pharmacogenetics
- Study aimed to identify genetic predictors of JAK inhibitor (JAKi) effectiveness in Taiwanese rheumatoid arthritis (RA) patients.
- 275 RA patients treated with tofacitinib, baricitinib, or upadacitinib were classified as Effective or Non-effective.
- Top candidate SNPs: CCL2 rs1024611/rs4586 and ITPA rs1127354 (all p<0.05).
- rs1024611 associated with higher CCL2 in dendritic cells; rs1127354 with higher ITPA in CD14+ monocytes.
- Non-effective patients showed higher CCL2 (p<0.001), especially in M0/M1/M2 monocytes.
- Effective patients had higher ITPA (p=0.018), notably in M2 monocytes (p<0.001).
- Independent replication using standardized ACR/EULAR outcomes is recommended.